Carregant...
Establishing a reasonable price for an orphan drug
BACKGROUND: This paper addresses the question of what a reasonable price for an orphan drug is. The research proposes a way to adjust an established payer/HTA body incremental cost-effectiveness threshold (CET) to take account of differences in patient populations and costs of research and developme...
Guardat en:
| Publicat a: | Cost Eff Resour Alloc |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7472708/ https://ncbi.nlm.nih.gov/pubmed/32908456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-020-00223-x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|